Lai Kai Medicine-B (02105) rose more than 13%. As of press time, it rose 13.68% to HKD 4.57 with a transaction amount of HKD 11.3051 million.
According to the Wisdom Finance APP, Lai Kai Medicine-B (02105) rose more than 13%. As of press time, it rose 13.68% to HKD 4.57 with a transaction amount of HKD 11.3051 million.
On the news front, Lai Kai Medicine recently announced that the company will release the final results of the Phase Ib study which investigated the efficacy and safety of LAE002 (afuresertib, an oral AKT inhibitor) in combination with fluorouracil plus oxaliplatin in the treatment of locally advanced or metastatic HR+/HER2- breast cancer patients who have failed standard treatment at the European Society for Medical Oncology (ESMO) annual meeting in 2024. This therapy demonstrated positive antitumor activity and good tolerability and safety in both the Chinese and U.S. populations of 31 subjects, as well as in the subgroup with PIK3CA/AKT1/PTEN alterations.
In addition, the company has made substantial progress in the development of targeted ActRII receptor product combinations. LAE102 is a monoclonal antibody developed by the company against ActRIIA, which received new drug clinical trial (IND) approvals for obesity in both China and the United States in April and May of this year, respectively. The Phase I clinical trial in China completed the first subject dosing in June 2024.